Impedimed Limited (AU:IPD) has released an update.
ImpediMed Limited reports a revenue increase to A$2.6 million in Q3 FY24 and a cash balance of A$30.7 million, despite net operating cash outflows of A$6.3 million due to one-off severance payments. The company has also undergone organizational changes aimed at cutting operating costs by 10-15% for FY25, alongside the appointment of a new SVP of Sales, Tim Benkovic, to bolster lead generation and sales execution.
For further insights into AU:IPD stock, check out TipRanks’ Stock Analysis page.
